A Phase II Pilot Trial of Bortezomib (PS-341 Velcade IND# 58 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The overall goal of this study is to find out if bortezomib can be safely added to the standard COG Re-Induction therapy for relapsed ALL, and be an effective therapy.
Description
The overall goal of this study is to find out if bortezomib can be safely added to the standard COG Re-Induction therapy for relapsed ALL, and be an effective therapy.
Details
| Condition | Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma (LL) |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX1910 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.